Blood test to track response in extensive-stage small cell lung cancer
Part of Cancer clinical trials.
This study checks whether a specialized blood test (ctDNA) can show how well treatment is working and help predict outcomes in people with newly diagnosed extensive-stage small cell lung cancer. It may help doctors spot response or risk earlier so treatment decisions can be better informed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent (agree to join the study).
- You were recently diagnosed with extensive-stage small cell lung cancer confirmed by biopsy or cell tests.
- Your cancer testing shows you are able to receive both radiation therapy and chemotherapy.
- You can return for follow-up visits and provide regular blood samples.
- You can share the clinical and pathology information the study needs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
This study uses a simple blood test to look at bits of tumor DNA (called circulating tumor DNA) to see how well your targeted therapy (TKI) is working. It helps doctors predict and monitor whether the treatment is effective for your advanced lung cancer.
This trial uses a special blood test to look for tiny cancer DNA to estimate your risk of the cancer getting worse after first immunotherapy. It aims to help doctors monitor progression earlier and more accurately in advanced lung cancer.
This study uses a special blood test to track minimal residual disease (tiny amounts of cancer that may remain) in people with stage IIIB-C non-small cell lung cancer after they receive initial chemotherapy plus immunotherapy. It may help doctors understand whether this blood test can guide further care and improve outcomes.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.